<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03460509</url>
  </required_header>
  <id_info>
    <org_study_id>SIVAA01</org_study_id>
    <nct_id>NCT03460509</nct_id>
  </id_info>
  <brief_title>Reversal With Low Doses of Sugammadex in Patients Undergoing Non-cardiac Surgery</brief_title>
  <official_title>A Randomized Double Blind Trial Comparing Reversal With Low Doses Of Sugammadex aFter Rocuronium-induced Neuromuscular Block Under General Anesthesia in Patients Undergoing Non-cardiac Surgery(TOF TRIAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital of Vestfold</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Hospital of Vestfold</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neuromuscular blocking agents (NMBA) are among the most commonly used drugs during general
      anesthesia and may induce complete muscle paralysis.They are used clinically to facilitate
      endotracheal intubation and to optimize surgical working conditions. Incomplete recovery from
      non-depolarising NMBAs continues to be a common problem in modern postoperative care unit and
      is associated with significant risk of microaspiration and hypoventilation which leads to
      pulmonary complications.Recently effective reversal of neuromuscular blockade has been
      described by use of lower dose of sugammadex the recommended without providing adequate
      answer to whether the lower dose is safe enough to avoid recurrent block.

      Hypotheses:

        1. Administration of sugammadex 0.25 mg/kg at TOF ratio 0.3 will successfully reverse
           (TOF=0.9) rocuronium induced neuromuscular block within 10 min.

        2. Recurrent block (TOF ratio &lt; 0.9) does not occur after reversal with low dose sugammadex
           0.25 mg/kg.

      The primary objective of this trial is to assess the dose-response characteristics of
      sugammadex in reversing rocuronium induced neuromuscular block and to identify the minimal
      effective dose

      Secondary objective is to assess the safety of different doses of sugammadex (recurrent block
      (TOF ratio &lt; 0.9) after reversal and the occurrence of adverse reactions)

      Sugammadex is a very expensive drug which limits its use i anaesthesia department. By
      optimising drug dosage it may have economic impact and contribute to a wider use of
      sugammadex to reverse neuromuscular block before extubation and thus avoid incomplete
      recovery. This may lead to less risk for postoperative pulmonary complications and thereby
      reduce morbidity and mortality after surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Doses of study drug will be 0 mg/kg Ideal Body Weight (IBW), 0.25 mg/kg IBW, 0.50 mg/kg IBW,
      1.0 mg/kg IBW and 2.0 mg/kg IBW. TOF will be measured every 10th second until full reversal.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">August 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The time from study drug administration to reaching a TOF ratio of 0.9.</measure>
    <time_frame>10 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patient with reoccurrence of neuromuscular block after initial reversal to TOF ratio 0.9.</measure>
    <time_frame>20 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse reactions in each group</measure>
    <time_frame>until discharge - 3 days</time_frame>
    <description>Adverse reactions (anaphylactic reaction, flushing, urticaria, erythematous rash, (severe) hypotension (BPsyst&gt; 75 mmHg), tachycardia (heart rate&gt; 120 beats/min), bradycardia (heart rate &lt;40 beats/min), swelling of tongue, swelling of pharynx, bronchospasm)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Postoperative Residual Curarization</condition>
  <condition>Neuromuscular Block</condition>
  <arm_group>
    <arm_group_label>Sugammadex 0 mg/kg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo NaCl 0,9%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugammadex 0,25 mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sugammadex 0.25 mg/kg IBW</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugammadex 0,5 mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sugammadex 0.50 mg/kg IBW</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugammadex 1mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sugammadex 1.0 mg/kg IBW</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugammadex 2mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sugammadex 2 mg/kg IBW</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>Dose-response</description>
    <arm_group_label>Sugammadex 0 mg/kg</arm_group_label>
    <arm_group_label>Sugammadex 0,25 mg/kg</arm_group_label>
    <arm_group_label>Sugammadex 0,5 mg/kg</arm_group_label>
    <arm_group_label>Sugammadex 1mg/kg</arm_group_label>
    <arm_group_label>Sugammadex 2mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient, both genders, undergoing any elective in-hospital surgical procedure under
             general anesthesia requiring rocuronium neuromuscular block.

          -  ASA I-IV

          -  Signed informed consent

        Exclusion Criteria:

          -  Patient less than 18 years of age

          -  Patient participating in another clinical study which could interfere with TOF trial.

          -  Patient with neuromuscular disease

          -  Patient from ICU

          -  BMI &gt; 30.0 kg/m2

          -  Patient scheduled for local or regional anesthesia only

          -  Patient undergoing general anesthesia without rocuronium

          -  Patient with hypersensitivity to NMBAs or sugammadex. Also hypersensitivity to any
             active substance or to any of the following excipient: Hydrochloric acid 3.7% (to
             adjust pH) and/or sodium hydroxide (to adjust pH) Water for injections .

          -  Renal dysfunction (GFR&lt;30 mL/min/1,73m2)

          -  Hepatic dysfunction

          -  Patient who have received sugammadex in the last 24 h.

          -  Pregnant or breastfeeding woman. Women in childbearing age must have a negative
             pregnant test before inclusion.

          -  Bradycardia (puls &lt;40)

          -  Hypotension (Systolic BP &lt;90 mmHg)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tayyba Aslam, MD</last_name>
    <phone>004798097489</phone>
    <email>tayybaaslam@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Espen Lindholm, MD, PHD</last_name>
    <phone>004792213346</phone>
    <email>espen.lindholm@siv.no</email>
  </overall_contact_backup>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>October 17, 2017</study_first_submitted>
  <study_first_submitted_qc>March 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2018</study_first_posted>
  <last_update_submitted>May 27, 2018</last_update_submitted>
  <last_update_submitted_qc>May 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital of Vestfold</investigator_affiliation>
    <investigator_full_name>Tayyba Aslam</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delayed Emergence from Anesthesia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

